Eculizumab (Anti-Complement C5)

製品コードA2538 別名: Anti-Human C5, Humanized Antibody 純度：99%

Eculizumab (Anti-Complement C5) is a long-acting humanized monoclonal antibody targeting against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research. MW: 145.5 KD.

サイズ（液体）	価格(税別)	在庫状況
1mg	JPY 44500	国内在庫なし(納期7~10日)
1mg*5	JPY 146500	お問い合わせ
1mg*25	JPY 445500	お問い合わせ

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

質量管理及び製品安全説明書

現在のバッチを見る：純度： 99% タンパク質濃度： 11.192mg/ml 内毒素：＜1EU/mg

生物活性

製品説明	Eculizumab (Anti-Complement C5) is a long-acting humanized monoclonal antibody targeting against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research. MW: 145.5 KD.

製品説明

CAS No.	219685-50-4
Molecular Weight	145.5 kDa
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Isotype	Human IgG1
Source	CHO
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Shipping	Shipped under low temperature conditions
Purification	AKTA
Sterility	0.2 μM filtered

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07010302	NOT_YET_RECRUITING	Drug: Rituximab (R)\|Drug: Eculizumab (Soliris®)\|Drug: Ravuli	NMOSD	Massachusetts General Hospital	2026-08-01	PHASE4
NCT07520318	NOT_YET_RECRUITING	Drug: bispecific anti-VEGF and anti-complement	Adults With Neovascular Age-related Macular Degeneration	Shenzhen Oculgen Biomedical Technology Co., Ltd.	2026-04-17	PHASE2; PHASE3
NCT07707687	RECRUITING	Drug: Eculizumab	Transplant-Associated Thrombotic Microangiopathy (TA-TMA)	First Affiliated Hospital of Zhejiang University	2026-07-10	PHASE2
NCT07747090	NOT_YET_RECRUITING	Drug: FXS6837 Capsule	Paroxysmal Nocturnal Hemoglobinuria	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	2026-12-10	PHASE3
NCT07410039	RECRUITING	Drug: Eculizumab+IVMP\|Drug: IVIG+IVMP\|Drug: IVMP	Neuromyelitis Optica Spectrum Disorder Attack	Chinese PLA General Hospital	2026-02-01	PHASE4
NCT06449001	RECRUITING	Drug: Danicopan	Paroxysmal Nocturnal Hemoglobinuria; PNH; Extravascular Hemolysis	Alexion Pharmaceuticals, Inc.	2025-08-11	PHASE3

(data from https://clinicaltrials.gov, updated on 2026-08-31)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須